Published in Gastroenterology on February 01, 1993
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Gut (1997) 1.38
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci (2002) 0.98
Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis. Ther Clin Risk Manag (2007) 0.87
Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut (1998) 0.86
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut (2002) 0.84
Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Gastroenterol Hepatol (N Y) (2011) 0.75
Mesalazine as maintenance treatment in Crohn's disease. Gastroenterology (1994) 0.75
Gastroenterology--II: Small and large bowel, pancreas and biliary system. Postgrad Med J (1994) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut (2000) 4.32
Occurrence of a new microsporidan: Enterocytozoon bieneusi n.g., n. sp., in the enterocytes of a human patient with AIDS. J Protozool (1985) 4.11
Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut (2008) 3.52
Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria. J Hepatol (1993) 3.24
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet (1996) 3.15
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology (2000) 2.78
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology (1990) 2.58
Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 2.47
Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet (1996) 2.41
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun (2001) 2.28
Gut-hormone profile in coeliac disease. Lancet (1978) 2.25
Diagnostic value of endoscopic capsule in patients with obscure digestive bleeding: blinded comparison with video push-enteroscopy. Endoscopy (2003) 2.20
Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol (2005) 2.16
An in-depth study of Crohn's disease in two French families. Gastroenterology (1993) 2.15
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1994) 2.07
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
Expansion by folinic acid of the peripheral blood progenitor pool after chemotherapy: its use in autografting in acute leukaemia. Br J Haematol (1990) 2.02
Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut (1981) 2.00
Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest (1985) 2.00
Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. Am J Gastroenterol (2001) 1.94
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93
Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol (1996) 1.89
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol (1997) 1.85
Incidence of inflammatory bowel disease in northern France (1988-1990). Gut (1994) 1.81
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology (1996) 1.73
Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology (1998) 1.71
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer (2006) 1.71
Clinical characteristics of Crohn's disease in 72 families. Gastroenterology (1996) 1.70
The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther (2011) 1.69
Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol (2000) 1.69
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology (1997) 1.69
Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology (1999) 1.68
Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. Dis Colon Rectum (1991) 1.65
Role of viscous guar gums in lowering the glycemic response after a solid meal. Am J Clin Nutr (1994) 1.65
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut (2005) 1.65
Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci (1989) 1.63
Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A (2001) 1.63
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut (1986) 1.63
Genetically related Escherichia coli strains associated with Crohn's disease. Gut (2001) 1.61
Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut (1985) 1.60
Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet (1995) 1.59
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab (2001) 1.58
Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium. Gut (1994) 1.57
Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood (1998) 1.56
Perioperative endoscopy of the whole small bowel in Crohn's disease. Gut (1993) 1.54
Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet (1994) 1.53
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther (2015) 1.51
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia (1997) 1.50
An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology (1994) 1.49
Anal lesions: any significant prognosis in Crohn's disease? Eur J Gastroenterol Hepatol (1997) 1.49
Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol (2001) 1.46
Clinical evaluation of the use of the M2A patency capsule system before a capsule endoscopy procedure, in patients with known or suspected intestinal stenosis. Endoscopy (2005) 1.45
Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer. Hum Genet (1999) 1.44
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2001) 1.44
[Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases]. Gastroenterol Clin Biol (1990) 1.44
Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut (1995) 1.44
Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum (2001) 1.44
Use of scanning electron microscopy to investigate dental calculus in dogs. Vet Rec (1990) 1.43
Colon capsule endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy (2012) 1.42
Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet (1978) 1.41
[Infliximab therapy for Crohn's disease anoperineal lesions]. Gastroenterol Clin Biol (2001) 1.40
Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. Am J Physiol (1998) 1.39
Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment. Gut (1999) 1.39
[Diagnostic and therapeutic management of patients with chronic inflammatory bowel disease]. Rev Epidemiol Sante Publique (1999) 1.39
[Acid-sensitive esophagus: natural history and effect on the quality of life. Comparison with gastroesophageal reflux]. Gastroenterol Clin Biol (2000) 1.39
Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology (1992) 1.39
Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut (2005) 1.39
Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood (1995) 1.39